Comparative efficacy of tube-sparing interventions for tubal ectopic pregnancy: a systematic review and network meta-analysis.

Eur J Obstet Gynecol Reprod BiolJul 9, 2026 (epub)
Clinical ResearchObstetrics & Gynecology

Can Shi, Han Wang, Tianqi Yang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis evaluated the efficacy and safety of tube-sparing interventions for tubal ectopic pregnancy in 3,211 patients across 35 randomized trials. The analysis found that most interventions did not significantly outperform single-dose methotrexate (MTX) for treatment success, with expectant management showing a lower success rate (RR 0.79, 95% CI 0.68-0.93).

Key findings

  • Expectant management had a lower treatment success rate (RR 0.79, 95% CI 0.68-0.93) compared to single-dose MTX.
  • Salpingotomy plus MTX ranked highest for success (SUCRA 91.0%) but was not statistically significant versus single-dose MTX.
  • Expectant management increased treatment failure risk (OR 3.33, 95% CI 1.09-10.13).
  • Multi-dose MTX was associated with increased adverse events (OR 1.63, 95% CI 1.18-2.24).

Why it matters

Understanding the comparative efficacy of tube-sparing interventions for tubal ectopic pregnancy is crucial for optimizing treatment strategies and improving patient outcomes. This analysis highlights the risks associated with expectant management and multi-dose MTX.

Source

PubMed · PMID 42468117

Published in Eur J Obstet Gynecol Reprod Biol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.